Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on January 11, 2016, covering events occurring on January 7, 2016. The filing primarily addresses executive compensation adjustments effective January 1, 2016, and announces an upcoming investor presentation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive and director compensation arrangements.
Material Changes
The Compensation Committee approved significant increases in base salaries and bonus targets for four executive officers, effective January 1, 2016:
- Yuval Cohen (CEO): Base salary increased from $240,000 to $370,000; bonus target increased from 33% to 50% of base salary.
- Mark Tepper (President & CSO): Base salary increased from $240,000 to $320,000; bonus target increased from 33% to 45% of base salary.
- Barbara White (CMO): Base salary increased from $300,000 to $345,000; bonus target increased from 33% to 40% of base salary.
- Sean Moran (CFO): Base salary increased from $200,000 to $305,000; bonus target increased from 33% to 40% of base salary.
Additionally, the annual fee for non-employee directors was increased from $25,000 to $35,000.
Equity Compensation and Outlook
The Company granted stock options under the 2014 Equity Compensation Plan to the same four executives:
- Dr. Cohen: 530,000 options
- Dr. Tepper: 240,000 options
- Dr. White: 240,000 options
- Mr. Moran: 175,000 options
Vesting is scheduled at 25% on the one-year anniversary of the grant date, with the remainder vesting in equal monthly installments over three years. Full acceleration occurs upon a change in control. The filing notes that cash bonuses for 2015 performance have not yet been determined.
Management is scheduled to present at the 8th Annual Biotech Showcase conference on January 12, 2016. The presentation slides are included as Exhibit 99.1 but are not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2014 Equity Compensation Plan to assess remaining capacity for future grants.
- Review the attached Exhibit 99.1 Investor Presentation for updated business strategy and clinical pipeline status.
- Monitor subsequent filings for the determination of 2015 cash bonus amounts for executive officers.
- Confirm the impact of the increased director fees on the Company's overall cash burn rate.